俞君英《Stem Cell》iPS文章

【字体: www.ebiotrade.com 时间:2009年04月08日 来源:生物通

编辑推荐:

  生物通报道,威斯康辛大学汤姆森实验室,医学实验室,病理学实验室等处的研究者在最近一期的《Stem Cell》上发表iPS研究新进展,文章的第二作者是iPS建立者之一华人科学家俞君英,文章标题为:Hematopoietic and Endothelial Differentiation of Human Induced Pluripotent Stem Cells。

分享到:
  

生物通报道,威斯康辛大学汤姆森实验室,医学实验室,病理学实验室等处的研究者在最近一期的《Stem Cell》上发表iPS研究新进展,文章的第二作者是iPS建立者之一华人科学家俞君英,文章标题为:Hematopoietic and Endothelial Differentiation of Human Induced Pluripotent Stem Cells

 

1997年,俞君英自北京大学生物系毕业后赴美国宾西法尼亚大学攻读生物博士学位,从事胚胎克隆领域的研究。2003年进入汤姆森实验室工作,并转向以人体皮肤细胞改组为干细胞的研究。

 

本篇文章中,研究人员主要对几种细胞的诱导多能性进行了全面的评价,用OP9分化系统鉴定了造血细胞系和内皮细胞系的iPS细胞的多能性。研究中的iPS分别来源于人类的胚胎成纤维细胞,新生儿的成纤维细胞,成人的成纤维细胞,用这些细胞来源建立了7iPS细胞系,诱导过程中用POU5F1SOX2NANOG,和LIN28几个诱导因子。研究者将这些iPS细胞与5株胚胎干细胞系(hESCH1H7H9H13H14)的多能性进行了对比。

 

研究结果发现,这些iPS细胞与人类胚胎干细胞一样具有相似的多能性,这些iPS细胞经诱导分化可表达造血细胞标记CD34CD43和内皮细胞标记CD31CD43iPS细胞系与人类胚胎干细胞系的分化多能性很相似。它们都能分化成造血祖细胞和内皮祖细胞。

 

这些喜人的结果表明,iPS细胞有望用于人类的血液疾病和某些遗传性疾病的治疗。

(生物通 小茜)

生物通推荐原文检索:Hematopoietic and Endothelial Differentiation of Human Induced Pluripotent Stem Cells

Abstract

Induced pluripotent stem cells (iPSCs) provide an unprecedented opportunity for modeling of human diseases in vitro, as well as for developing novel approaches for regenerative therapy based on immunologically compatible cells. In this study, we employed an OP9 differentiation system to characterize the hematopoietic and endothelial differentiation potential of seven human iPSC lines obtained from human fetal, neonatal, and adult fibroblasts through reprogramming with POU5F1, SOX2, NANOG, and LIN28 and compared it with the differentiation potential of five human embryonic stem cell lines (hESC, H1, H7, H9, H13, and H14). Similar to hESCs, all iPSCs generated CD34+CD43+ hematopoietic progenitors and CD31+CD43– endothelial cells in coculture with OP9. When cultured in semisolid media in the presence of hematopoietic growth factors, iPSC-derived primitive blood cells formed all types of hematopoietic colonies, including GEMM colony-forming cells. Human induced pluripotent cells (hiPSCs)-derived CD43+ cells could be separated into the following phenotypically defined subsets of primitive hematopoietic cells: CD43+CD235a+CD41a± (erythro-megakaryopoietic), lin–CD34+CD43+CD45– (multipotent), and lin–CD34+CD43+CD45+ (myeloid-skewed) cells. Although we observed some variations in the efficiency of hematopoietic differentiation between different hiPSCs, the pattern of differentiation was very similar in all seven tested lines obtained through reprogramming of human fetal, neonatal, or adult fibroblasts with three or four genes. Although several issues remain to be resolved before iPSC-derived blood cells can be administered to humans for therapeutic purposes, patient-specific iPSCs can already be used for characterization of mechanisms of blood diseases and for identification of molecules that can correct affected genetic networks. STEM CELLS 2009;27:559–567

我来说两句(0)

[Ctrl+Enter]

加载读者评论......
  • 搜索
  • 国际
  • 国内
  • 人物
  • 产业
  • 热点
  • 科普
  • 急聘职位
  • 高薪职位

知名企业招聘

  • 国外动态
  • 国内进展
  • 医药/产业
  • 生态环保
  • 科普/健康

新闻专题

相关文章:

    加载相关文章......

今日文章:

    加载今日文章......

生物通首页 | 今日动态 | 生物通商城 | 人才市场 | 核心刊物 | 特价专栏 | BBS交流

版权所有 生物通

Copyright© eBiotrade.com, All Rights Reserved

联系信箱:

粤ICP备09063491号